(Updates with CVS Health's reply in the third paragraph.)
A federal judge in Missouri declined Tuesday to accept the request of pharmacy benefit managers to enjoin the Federal Trade Commission's in-house case alleging they systematically preferred high-list-price insulin products in violation of the FTC Act.
The complaint, originally filed last November by CVS Health's (CVS) CVS Caremark, UnitedHealth Group's (UNH) Optum Rx and Cigna Group's (CI) Express Scripts, called the FTC's administrative proceeding unconstitutional and sought an injunction to stop it.
"Drugmakers alone set the price of insulin, but the FTC has already demonstrated it is not interested in considering our full perspective on this topic," a CVS spokesperson told MT Newswires via email. "We will continue to fight this unfair and unconstitutional proceeding."
UnitedHealth and Cigna did not immediately reply to requests for comment.
Price: 66.32, Change: +0.75, Percent Change: +1.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。